Secarna Pharmaceuticals Highlights Promising Data on SECN-15 at AACR

Secarna Pharmaceuticals will showcase new data on their antisense oligonucleotide, SECN-15, at the AACR 2025 Annual Meeting. The data focuses on SECN-15 as a monotherapy and in combination with immune checkpoint inhibitors (ICIs), aiming to enhance ICI efficacy. Research indicates SECN-15 modulates the tumor microenvironment, targeting the protein Neuropilin 1 (NRP1).

NRP1 is linked to negative cancer outcomes. Overexpression occurs in several cancers including gastric cancer. SECN-15's mechanism may offer improved treatment options where ICIs alone have limited success. Findings illustrated SECN-15's ability to downregulate NRP1, enhancing T cell activity and tumor eradication in mice. Secarna plans to initiate Phase I/II trials in mid-2026.